Nonpurulent Cellulitis

Clinical Snapshot

Nonpurulent cellulitis is an acute infection of the dermis and subcutaneous tissue, usually driven by beta-hemolytic streptococci.^[1] It produces diffuse warmth, tenderness, edema, and poorly defined erythema or discoloration. The first therapeutic decision is not "which antibiotic?" but "is this truly cellulitis, and is it uncomplicated?" Bilateral lower-leg redness is far more likely to be a noninfectious mimic than bacterial cellulitis.

Recognize the Condition

Diffuse, poorly demarcated erythema, warmth, and swelling of the lower leg and foot consistent with cellulitis

Nonpurulent cellulitis of the lower leg — diffuse warmth and poorly demarcated erythema without a drainable focus. (cbinrva, CC BY-SA 4.0, Wikimedia Commons)

Acute unilateral warmth, tenderness, and swelling.
Poorly demarcated erythema in light skin; in darker skin, inflammation may appear purple, brown, grey, or dusky, or may be better detected by warmth, edema, and tenderness than by colour change.^[2]
May have lymphangitic streaking or regional lymphadenopathy.
No drainable abscess or dominant purulent focus — this is what separates it from purulent cellulitis.

Risk Factors

Skin breaks, ulcers, wounds, fissures, or excoriations.
Interdigital tinea pedis.
Chronic edema/lymphedema and venous disease.
Previous cellulitis.
Diabetes, obesity, or immunosuppression.

Red Flags & Refer

Urgent/emergency assessment for any of the following:

Pain out of proportion to appearance.
Rapid progression.
Bullae.
Necrosis.
Crepitus.
Numbness.
Hypotension.
Severe systemic toxicity.
Orbital/facial deep-space involvement.
Septic joint concern.
An immunocompromised patient with severe infection.
Failure of oral therapy.

Assessment & Diagnosis

Confirm infection

Document onset, borders, warmth, tenderness, edema, portal of entry, systemic symptoms, and comorbidities. Check interdigital spaces for tinea. Routine cultures are not useful in uncomplicated nonpurulent cellulitis because there is no accessible infected material to sample.^[3]

Actively exclude mimics

Venous stasis dermatitis

Commonly bilateral, chronic, itchy/scaly; improves with elevation.

Deep vein thrombosis

Swelling/pain without the classic superficial inflammatory pattern — investigate when risk is significant.

Gout

Joint-centred severe pain.

Herpes zoster

Grouped vesicles in a dermatomal pattern with a neuropathic prodrome.

Treatment Targets

Stop spread and systemic progression.
Resolve pain, warmth, and edema.
Prevent abscess, bacteremia, and recurrence.
Correct the portal of entry — tinea pedis, chronic skin breakdown, ulcers.

Choose Initial Treatment

Direct treatment rule

Mild, uncomplicated disease

1st line: oral cephalexin targeting streptococci/MSSA.

Do not add MRSA-active therapy routinely.

Moderate/severe disease, or inability to take oral therapy

1st line: IV cefazolin and urgent higher-level assessment.

Severe beta-lactam allergy

Alternative: clindamycin (oral).

Alternative for severe/parenteral need: vancomycin IV.

Non-Pharmacologic Treatment

Elevate the affected limb above heart level when feasible.
Use cool wet compresses for comfort.
Mark the erythema border and record the time/date for objective follow-up.
Treat tinea pedis, ulcers, eczema, and edema.
For chronic lower-limb edema, initiate appropriate compression once acute pain/inflammation permits and contraindications are excluded — daily compression stocking use reduces recurrent cellulitis.^[4]

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Cephalexin Preferred	Mild outpatient 1st line	500 mg PO QID, generally 5 days; extend if response is incomplete	GI upset, hypersensitivity	Renal adjustment may be required.
Cefadroxil Alternative	Outpatient alternative	500 mg PO daily-BID	GI upset, hypersensitivity	Similar MSSA/streptococcal coverage to cephalexin.
Clindamycin Alternative	Beta-lactam allergy	300-450 mg PO TID	C. difficile infection risk	Use when a beta-lactam cannot be used and local susceptibility is acceptable.
Cefazolin Preferred (parenteral)	Moderate/severe disease requiring IV therapy	1-2 g IV Q8H	Hypersensitivity, phlebitis	Hospital/ambulatory IV management of streptococcal/MSSA cellulitis.
Vancomycin Special situation	MRSA concern or severe beta-lactam allergy	Weight-based IV dosing with institutional AUC monitoring	Nephrotoxicity, infusion reaction	Reserve for severe disease with MRSA concern or when preferred beta-lactams cannot be used.
Sulfamethoxazole/Trimethoprim Special situation	Add-on MRSA coverage only	1-2 DS tablets PO BID	Hyperkalemia, rash, cytopenias	Only when MRSA risk/purulence is present; not preferred as streptococcal monotherapy.

Special Populations

Pregnancy

Cephalexin, cefazolin, and other appropriate beta-lactams are generally preferred when the organism is susceptible. Clindamycin is an alternative when beta-lactams cannot be used.

Diabetes

Do not automatically treat simple cellulitis as a diabetic-foot infection. If ulceration, ischemia, neuropathy, or deep-foot involvement is present, move to a diabetic-foot-infection pathway instead.

Severe beta-lactam allergy

Confirm the allergy phenotype. Severe delayed reactions such as SJS/TEN require avoidance of implicated beta-lactams; use a non-beta-lactam regimen guided by severity and local susceptibility.

Monitoring & Follow-Up

Reassess within 48-72 hours. The skin can look transiently more inflamed in the first 24-48 hours even when therapy is effective — judge the whole patient (pain, fever, spread rate, systemic status), not the erythema border alone. Improvement is demonstrated by stabilization of borders, less tenderness/warmth, and improved systemic symptoms.

Treatment Failure / Next Step

Confirm diagnosis — reconsider stasis dermatitis, DVT, gout, and zoster.
Look for a hidden abscess, foreign body, or deeper focus.
Check adherence and antibiotic exposure.
Add MRSA-active therapy only if purulence or MRSA risk emerges.
Escalate to IV/hospital care if progression continues or systemic illness develops.

Common Errors to Avoid

Treating bilateral red legs as cellulitis without reconsidering stasis dermatitis.
Adding MRSA coverage to every nonpurulent cellulitis case.
Calling mild early inflammatory extension at 24 hours an automatic treatment failure.
Ignoring tinea pedis and chronic edema as portals of entry.
Missing necrotizing fasciitis because the erythema is not dramatic.

Clinical Decision Algorithm

Algorithm A — Nonpurulent cellulitis triage

Acute unilateral warm, tender, swollen, poorly demarcated skin infection without drainage or abscess

Exclude mimic/emergency: bilateral stasis dermatitis, DVT, gout, zoster, necrotizing infection, orbital/deep-space infection

Mild, no systemic toxicity

Cephalexin PO 1st line; elevate limb and treat the portal of entry

Moderate/severe, deep involvement, rapid spread, major comorbidity, or systemic toxicity

IV therapy and urgent physician/hospital assessment; cefazolin or equivalent; add MRSA coverage only when indicated

Algorithm B — 48-hour reassessment

Cellulitis after antibiotic initiation

Stable; erythema slightly deeper/extends early but systemic status improving

Continue regimen — early inflammatory worsening can occur before improvement

Rapid progression, new severe pain, bullae, necrosis, hypotension, or no improvement after 48-72 h

Reassess diagnosis and abscess/necrotizing infection; escalate care

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Oral therapy

Drug	Dosage	Adverse effects	Comments
Cephalexin	Adults: 500 mg PO QID, generally 5 days; extend if response is incomplete Children: 25-50 mg/kg/day divided Q6H PO	GI upset, hypersensitivity	Mild outpatient 1st line; renal adjustment may be required.
Cefadroxil	Adults: 500 mg PO daily-BID Children: 20 mg/kg PO once daily (max 500 mg/day)	GI upset, hypersensitivity	Outpatient alternative.
Cefuroxime	Adults: 500 mg PO BID Children: 20-30 mg/kg/day divided Q12H PO (max 500 mg/dose)	GI upset, hypersensitivity	Selected allergy/second-line option when a first-generation cephalosporin is unsuitable.
Clindamycin	Adults: 300-450 mg PO TID Children over 1 month: 25-40 mg/kg/day divided Q8H PO (max 450 mg/dose)	C. difficile infection risk	Beta-lactam allergy option when local susceptibility is acceptable.

Parenteral therapy (moderate/severe)

Drug	Dosage	Adverse effects	Comments
Cefazolin	Adults: 1-2 g IV Q8H Children: 50-100 mg/kg/day divided Q8H IV (max 6000 mg/day)	Hypersensitivity, GI upset, phlebitis	Hospital/ambulatory IV first line.
Cloxacillin	Adults: 2 g IV Q6H (common hospital dose) Children: 25-50 mg/kg Q6H IV (max 2000 mg/dose)	Hypersensitivity, hepatic effects, phlebitis	Selected IV MSSA-dominant infection.
Vancomycin	Adults: 1 g Q12H (or 15 mg/kg Q8-12H) IV, institutional AUC monitoring Children: 45-60 mg/kg/day divided Q6-8H IV	Nephrotoxicity, infusion reaction	MRSA or severe beta-lactam allergy.

References

Cellulitis: a review — JAMA (Raff AB, Kroshinsky D). JAMA 2016;316(3):325-337
Skin diversity erythema description guidance — British Association of Dermatologists (Gass M, Dadzie OE, Dlova N, et al.). February 2021
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America — Clinical Infectious Diseases (Stevens DL, Bisno AL, Chambers HF, et al.). Clin Infect Dis 2014;59(2):e10-e52
Compression therapy to prevent recurrent cellulitis of the leg — New England Journal of Medicine (Webb E, Neeman T, Bowden FJ, et al.). N Engl J Med 2020;383(7):630-639

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.